Mosaic Therapeutics secures £22.5m Series A funding from Syncona Investment Management and Cambridge Innovation Capital to advance targeted oncology therapies
The Series A round was backed by Syncona Investment Management and Cambridge Innovation Capital to support pipeline progression and team expansion.
Mosaic Therapeutics develops targeted oncology therapies by combining advanced computational methods with next-generation cancer models. The firm builds upon research originating from the Wellcome Sanger Institute and the Netherlands Cancer Institute.
Mosaic Therapeutics has secured £22.5m in a Series A funding round backed by Syncona Investment Management and Cambridge Innovation Capital. The capital will support the advancement of the company pipeline through preclinical development alongside recruitment for experimental biology and computational teams. Brian Gladsden has also joined the firm as chief executive officer following leadership roles at Novartis Oncology and Bayer.
From the founder
"I believe that Mosaic is ideally positioned to resolve the complexity of cancer, to discover and develop targeted therapies that address areas of high unmet need. The people, platform, connection to a world-leading genomics research institute, and strong investor partnerships are truly best in class. To receive funding from such high calibre investors is testament to the potential of Mosaic’s technology and multidisciplinary team, as well as the exceptional support provided by the Wellcome Sanger Institute."
Brian Gladsden
CEO at Mosaic Therapeutics
Investor perspective
"The unprecedented insights provided by the genomic revolution have enabled more targeted drug development, with drug targets being de-risked by genetics or data. This approach to drug discovery is a focus for us at Syncona and Mosaic is a great example of a company built around this concept. With a differentiated strategy that can accelerate entry to the clinic, and the potential for application in a number of oncology settings in cancers which have previously been difficult to treat, we are excited for the potential of this platform. The opportunity for the Company, and most importantly for patients, is significant. I am thrilled that Brian has joined Mosaic to lead the next stage of the Company’s growth, and look forward to building this business in partnership with its world-class team."
Magdalena Jonikas
Lead Partner, Syncona Investment Management
Use of funds
- 01Grow the team
- 02Fund research and development
Investors
Categories
About the company
Mosaic Therapeutics
Mosaic Therapeutics develops targeted oncology treatments using advanced computational methods and cancer genomics.